ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma